19 May 2013
Keywords: Merck, Medivation, Astellas, ARIAD, Ridaforolimus, Ponatinib,
Article | 07 June 2011
The ongoing annual meeting of the American Society of Clinical Oncology (ASCO) saw another batch of good news from drugmakers, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 June 2011
17 May 2013
© 2013 thepharmaletter.com